Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study

Frontiers in Molecular Biosciences 2026 Open access

Read full text
Authors: Yao Sun, Yuxia Zhang, Jiayi Liu, Yanting Yu, Min Huan Wu, Qing Yin, Yujia Wang, Ziyu Liang, Biao Huang, Ri-Ning Tang, Huimin Xia
DOI: 10.3389/fmolb.2026.1770916
Cited by: 1
References: 24

Abstract

Background: Standard rituximab (RTX) regimens for primary membranous nephropathy (PMN) may result in subtherapeutic RTX exposure within 2-3 months due to altered pharmacokinetics, potentially contributing to delayed remission, incomplete immunologic control, and relapse. We evaluated whether an exposure-optimized RTX strategy combined with structured glucocorticoid tapering was associated with improved clinical and immunologic outcomes in PMN. Methods: weekly ×4 weeks). Median follow-up time was 17.0 (IQR: 12.5-25.6) and 14.8 (IQR: 12.0-27.1) months for GC/MRTX and SRTX groups, respectively. Primary endpoint: complete remission (CR; proteinuria

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Pregnancy and Medication Impact

Publication details

Journal / source
Frontiers in Molecular Biosciences
Publisher
Frontiers Media SA
Volume
13
Pages
1770916–1770916
Publication date
4 March 2026
Language
EN